Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech for less than cash value -- Ignore unavailable to you. Want to Upgrade?

To: rkrw who wrote (517)	7/24/2019 9:42:52 AM
From: rkrw	1 Recommendation Recommended By ghmm Respond to of 684

First hit, Jounce with a $50m upfront from Celgene,.

To: rkrw who wrote (517)	7/27/2019 11:06:25 AM
From: BulbaMan	Read Replies (1) \| Respond to of 684

Thanks for posting the list! I wonder if it would be useful to check for the ages of the CEOs of the biotechs selling below cash. I’m assuming that the cash rich biotechs are pipeline poor. Also that an elderly CEO would be motivated to retire on a “high” (or at least “higher”) note rather than just slowly burn away the company cash (or get pushed out by disgruntled investors). So, prior to retiring, they would actively either: 1) Seek to sell the company at a premium, even if only at its cash value. 2) Seek to merge with another biotech that’s cash poor but pipeline rich. I know I’m not the first to think of CEO age as important but have never seen a study as it relates to cash rich biotechs. The subject pool does appear large enough for such a study to make sense. Peace & good health, Bulba

To: rkrw who wrote (517)	7/27/2019 7:20:09 PM
From: bmaz001	Respond to of 684

@buysidebio posted this on Twitter recently: "Biotech & Pharma names with <2 years of cash that have not raised in 2019. Estimates may be slightly off. Market cap >80M. 115 companies in total." 2 years of cash left Maybe companies common to your list and buysidebio's are worth a closer look: ABUS, ACRS, APTX, FBIO, FPRX, IFRX, MNLO, MRNS, NTEC and VSTM

To: rkrw who wrote (517)

8/26/2019 7:50:42 AM

From: rkrw

1 Recommendation

Recommended By
ghmm

Respond to of 684

Updated for Q2 burn.

59 at or below cash, by my calcs 16 of which will be above cash by 9.30, 13 have sizable debt making it misleading.

Ttph,

Adxs,

Nvln,

Life,

Zfgn,

Mlnt,

Tril,

Srra,

Acrs,

Pti,

Adro,

Tnxp,

Ifrx,

Endp,

Isee,

Cldx,

Snna,

Prtk,

Acor,

Cycc,

Vvus,

Vstm,

Cytr,

Hepa,

Nlnk,

Clvs,

Tcon,

Jnce,

Agtc,

Nviv,

Vlrx,

Rgls,

Glyc,

Prta,

Ancn,

Fbio,

Nvus,

Sybx,

Ctic,

Rexn,

Vblt,

Ntec,

Clbs,

Cnat,

Alt,

Aptx,

Mgen,

Svra,

Kzr,

Blrx,

Mrsn,

Otic,

Abio,

Cbio,

Fprx,

Abus,

Htbx,

Adms,

Blcm,

Mnlo,

Clsd,